Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...